Albireo Pharma Inc Recommendation mean
What is the Recommendation mean of Albireo Pharma Inc?
The Recommendation mean of Albireo Pharma Inc is 1.13
What is the definition of Recommendation mean?
Recommendation mean is the mean of analysts’ ratings of the stock ranging from 1.0 (strong buy) to 5.0 (strong sell).
Mean of recommendations is an average of ratings from different analysts but it should still be used with other research and investment metrics in order to make investment decisions. It is important to understand a firm's entire scale when assimilating ratings. Additionally, analyst recommendations on stocks owned by firms employing them may be seen as potentially biased.
Financial analysts are often employed by mutual and pension funds, hedge funds, securities firms, banks, investment banks, insurance companies, and other businesses, helping these companies or their clients make investment decisions. Financial analysts employed in commercial lending perform "balance sheet analysis," examining the audited financial statements and corollary data in order to assess lending risks. In a stock brokerage house or in an investment bank, they read company financial statements and analyze commodity prices, sales, costs, expenses, and tax rates in order to determine a company's value and project future earnings. In any of these various institutions, the analyst often meets with company officials to gain a better insight into a company's prospects and to determine the company's managerial effectiveness.
Usually, financial analysts study an entire industry, assessing current trends in business practices, products, and industry competition. They must keep abreast of new regulations or policies that may affect the industry, as well as monitor the economy to determine its effect on earnings.
Recommendation mean of companies in the Health Care sector on NASDAQ compared to Albireo Pharma Inc
What does Albireo Pharma Inc do?
Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and other adult liver diseases and disorders. Albireo's lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases with Phase 3 pivotal trials in PFIC, Alagille syndrome and biliary atresia. The Company completed IND-enabling studies for new preclinical candidate A3907 this year and plans to advance development in adult liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year.
Companies with recommendation mean similar to Albireo Pharma Inc
- Acadia Pharmaceuticals Inc has Recommendation mean of 1.11
- Axonics Inc has Recommendation mean of 1.11
- VICI Properties Inc has Recommendation mean of 1.11
- Aurinia Pharmaceuticals Inc has Recommendation mean of 1.11
- Atreca Inc has Recommendation mean of 1.11
- Natera Inc has Recommendation mean of 1.11
- Albireo Pharma Inc has Recommendation mean of 1.13
- AdaptHealth Corp has Recommendation mean of 1.14
- Nomad Foods has Recommendation mean of 1.14
- Phillips 66 has Recommendation mean of 1.14
- Aldeyra Therapeutics Inc has Recommendation mean of 1.14
- Compugen Ltd has Recommendation mean of 1.14
- Haemonetics has Recommendation mean of 1.14